New Delhi, Jul 14 (PTI) The initial public offer of Anthem Biosciences Ltd got subscribed 73 per cent on the first day of share sale on Monday.

The initial share sale received bids for 3,21,13,406 shares against 4,40,70,682 shares on offer, according to NSE data.

Also Read | How To Check Lottery Sambad Results: A Comprehensive Guide for Indian Lottery Enthusiasts.

Non-institutional Investors category garnered 1.55 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 58 per cent. The portion for Qualified Institutional Buyers (QIBs) received 37 per cent subscription.

Anthem Biosciences has raised Rs 1,016 crore from anchor investors.

Also Read | MHADA Lottery 2025: MHADA Announces Konkan Housing Lottery for 5,285 Flats and 77 Residential Plots, Registration Begins Today at housing.mhada.gov.in; Know Important Dates and How To Apply.

The Rs 3,395-crore IPO of the Bengaluru-based firm will close on July 16. The price band has been fixed at Rs 540-570 per share.

Since the IPO is entirely an offer-for-sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders.

Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing.

It also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.

JM Financial, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)